Finerenone
Brand names: Kerendia
At a glance
- Medicare prescriptions, 2024
- 324,850
- Medicare drug cost
- $307.5M
- Average cost per prescription
- $947
- Clinicians who prescribed it
- 8,382
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Kerendia is indicated to reduce the risk of: sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM). cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%.
From the FDA-approved prescribing information (label dated August 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Nephrology (Kidney) 35.6%
- Internal Medicine 18.7%
- Family Medicine 16.2%
- Nurse Practitioners 11.5%
- Endocrinology & Diabetes 7.7%
- Physician Assistants 4.2%
- Cardiology 2.1%
- Interventional Cardiology 0.9%
- Geriatric Medicine 0.8%
- General Practice 0.8%
- Pulmonology 0.2%
- Hospitalist 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2021–2024
Medicare prescriptions rose 11,385% from 2021 to 2024.
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Bayer HealthCare Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | pink oval tablet, 4 mm | 10 FI |
| 20 mg | yellow oval tablet, 4 mm | 20 FI |
| 40 mg | orange oval tablet, 11 mm | 40 FI |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $8.0M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Bayer HealthCare Pharmaceuticals Inc. $8.0M
- Bayer Puerto Rico Inc. $17,820
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.